DKFZ,Genetic Immunity to develop HPV therapeutic vaccine
Led by Lutz Gissmann, the Division of Genome Modifications and Carcinogenesis set to begin assessing the therapeutic efficacy of the DKFZ’s HPV-specific plasmid DNA as part of the
Bristol Myers Squibb (BMS) is set to merge its separate research and development (R&D) departments into a single entity, effective from 1 January 2027.